INTRODUCTION
============

Cystic fibrosis (CF) is a genetic disease that compromises the normal physiology of several different organs. The main cause of morbidity and mortality in these patients is respiratory system involvement^[@r1]^. As with other chronic respiratory disorders, ventilation impairment begins during sleep, especially during the rapid eye movement (REM) stage^[@r2],[@r3]^. In children, the REM stage of sleep is of longer duration than in adults. Although overnight polysomnography is costly and access is limited, it is considered the gold standard test for evaluation of respiratory abnormalities during sleep^[@r4],[@r5]^.

Cystic fibrosis patients exhibit decreases in sleep oxyhemoglobin saturation (SpO~2~) that are associated with reduced intercostal muscle activity, irregular breathing patterns, and hypoventilation caused by reduced tidal volume and minute ventilation^[@r2]^. Hypoxemia and hypercapnia during sleep are common findings in patients with advanced lung disease, but they are also described in some individuals with mild or moderate disease^[@r6]-[@r8]^. Even in the absence of frank hypoxemia, nocturnal SpO~2~ is lower in the CF pediatric population than in healthy controls^[@r5],[@r7],[@r9],[@r10]^. For nocturnal carbon dioxide (CO~2~) estimation, a study comparing CF children with healthy controls found an association between peak CO~2~ and CF^[@r11]^. Polysomnography (PSG) findings are conflicting with regard to the greater frequency of obstructive sleep apnea in CF children compared to controls^[@r5],[@r7],[@r9],[@r11],[@r12]^.

There are also previous studies that have investigated associations between sleep-disordered breathing (SDB) and waking clinical and functional variables (such as spirometry data). These studies have reported different and even conflicting results^[@r7],[@r13]-[@r15]^. Furthermore, there are studies that have described improvements in CF disease after treatment of obstructive sleep apnea-hypopnea syndrome (OSAHS)^[@r16]-[@r18]^.

Although relevant, studies of SDB in CF pediatric populations have reported discrepant findings and are subject to limitations^[@r19]^. Therefore, the objectives of this study were to describe SDB frequency and to study associations between changes in polysomnography respiratory indexes and available clinical data.

MATERIAL AND METHODS
====================

This was a cross-sectional study performed by review of medical records for 2015 and 2016 from a CF center. The project was approved by the Institutional Ethics Committee (number 1.294.834). Participants were recruited from among patients in follow-up at the multidisciplinary CF outpatient clinic at a tertiary hospital in Porto Alegre (Southern Brazil). Subjects included were aged from 2 to 20 years and had undergone nocturnal PSG during the previous two years. Exclusion criteria were use of nocturnal ventilatory support, prior lung transplantation, unavailability of medical records and irregular follow-up.

Subjects had been referred to the outpatient clinic for CF investigation, either because of symptoms of CF (such as recurrent respiratory infections, low weight gain, and fatty stools)^[@r1]^ or because of an abnormal newborn CF screening test. Sweat testing and/or CFTR genotyping was used to confirm CF.

The following information was extracted from medical records and used for patients\' clinical, functional and sleep evaluation:

1\. Date of birth, sex, age of diagnosis;

2\. Anthropometric data (weight and height) and indicators of nutritional status (weight for age, height for age and body mass index - BMI), which were classified by percentiles and Z scores, according to National Center for Health Statistics charts^[@r20]^;

3\. Comorbidities, treatment, number of exacerbations per year, Shwachman score^[@r15],[@r21]^ and bacterial airway colonization (chronic colonization by *Pseudomonas aeruginosa* \[PA\] was defined as PA present in at least 50% of cultures over one year)^[@r22],[@r23]^;

4\. Lung function data, such as forced expiratory volume in first second (FEV~1~), forced vital capacity (FVC), FEV~1~/FVC ratio and forced expiratory flow from 25% to 75% of FVC (FEF~25-75~). The Global Lung Function Initiative international equation was used as the reference for percentiles and for Z scores for age, height, and sex^[@r24]^. Examinations were performed using Koko equipment (PDS Instrumentation, Inc., Louisville, CO, USA) and all procedures were conducted in accordance with American Thoracic Society criteria^[@r25]^;

5\. Polysomnography data included: sleep efficiency, sleep latency for sleep and REM sleep onset, apnea-hypopnea index per hour of sleep (AHI), obstructive AHI index per hour of sleep (OAHI, where central apneas were discounted in the numerator calculation), baseline and minimal oxyhemoglobin saturation, desaturation index (which was defined as at least a 3% reduction from baseline SpO~2~), mean values of exhaled CO~2~ (EtpCO~2~) in REM and NREM sleep and when awake, total time and percentage of total sleep time (TST) with measured value of high carbon dioxide, and highest (peak) sleep EtpCO~2~ value. Examination data were recorded using Alice 5^®^ (Philips Respironics) equipment, with the exception of one examination (which was performed with Bio-Logic^®^). In all subjects, the test was conducted at night with spontaneous breathing and the study was performed according to international American Academy of Sleep Medicine recommendations.

For statistical analysis, categorical variables were described as absolute and relative frequencies, and continuous variables as mean and standard deviation. Continuous variables outcomes were compared using the t-test. The fisher\'s exact test or chi-square test were used for associations between categorical variables. Spearman and Pearson tests were used for correlation analysis, as appropriate for distribution of variables. A 0.05 significance (*p*) cutoff was used.

RESULTS
=======

Ninety-one subjects are followed at the PUCRS CF Center and 16 cases had undergone PSG. Among these individuals with PSG records, 75% were male and mean age was 11 ± 5.6 years. Thirteen subjects had identified genotypes (\> 80% had at least one allele for F508del). All subjects had pancreatic insufficiency and were on enzyme replacement therapy.

The mean AHI for the sample was 1.4 ± 1.8 events per hour of sleep and after exclusion of central apneas (OAHI), the mean value was 1.2 ± 1.7 events per hour of sleep. Subjects\' mean sleep SpO~2~ was 95.7 ± .3%, with a minimum of 89.5 ± 3.9%. Fifteen subjects (93%) had zero percent of their TST with SpO~2~ below 90%. Of fourteen individuals for whom information about EtpCO~2~ measurements was available, just one individual had a CO~2~ peak higher than 50mmHg and remained 0.1% of TTS (approximately 0.4 minutes) with this range. Mean EtpCO~2~ values during NREM and REM sleep were 34.3 ± 3.1 mmHg and 35.1 ± 2.6 mmHg respectively and the whole-sample peak value was 42.1 ± 3.5 mmHg. When the parameters for normality were defined as AHI less than or equal to one hourly sleep event and an SpO~2~ nadir greater than or equal to 90%, only six subjects (37.5% of the total, mean age of 11.7 years and BMI Z score of - 0.18) met these criteria for normality. [Table 1](#t1){ref-type="table"} lists additional characterization data and results broken down by respiratory findings (defined as normal for patients with AHI less than or equal to one event per hour of sleep and an SpO~2~ nadir greater than or equal to 90%).

###### 

Clinical and functional characteristics of study participants.

  Information                                                     All patients    Normal          Abnormal        p
  --------------------------------------------------------------- --------------- --------------- --------------- -------
  Age; mean ± SD                                                  11.0 ± 5.6      11.7 ± 6.4      10.6 ± 5.4      0.738
  Boys; n (%)                                                     12/16 (75%)     3/6 (50%)       9/10 (90%)      0.118
  BMI Z score; mean ± SD                                          0.13 ± 0.61     -0.18 ± 0.58    0.32 ± 0.57     0.125
  ≥ one DF508 allele; n (%)                                       11/13 (84.6%)   3/5 (60%)       8/8 (100%)      0.128
  Chronic PA airway colonization; n(%)                            7/16 (43.7%)    4/6 (66.6%)     3/10 (30%)      0.302
  Respiratory exacerbations/year; mean ± SD                       3.1 ± 2.0       2.0 ± 1.3       4.0 ± 2.2       0.067
  FVC %predict; mean ± SD[†](#TFN2){ref-type="table-fn"}          92.22 ± 23.22   91.54 ± 27.74   92.60 ± 22.16   0.944
  FVC Z score; mean ± SD[†](#TFN2){ref-type="table-fn"}           -0.67 ± 1.99    -0.74 ± 2.39    -0.64 ± 1.89    0.937
  FEV~1~ %predict; mean ± SD[†](#TFN2){ref-type="table-fn"}       87.95 ± 26.21   91.04 ± 27.03   86.23 ± 27.24   0.758
  FEV~1~ Z score; mean ± SD[†](#TFN2){ref-type="table-fn"}        -0.99 ± 2.19    -0.76 ± 2.34    -1.12 ± 2.24    0.789
  FEV~1~/FVC Z score; mean ± SD[†](#TFN2){ref-type="table-fn"}    -0.68 ± 1.30    -0.04 ± 0.65    -1.04 ± 1.47    0.106
  FEF~25-75~ Z score; mean ± SD[†](#TFN2){ref-type="table-fn"}    -1.03 ± 1.92    -0.30 ± 1.31    -1.43 ± 2.15    0.247
  Snoring; n (%)[‡](#TFN3){ref-type="table-fn"}                   5/15 (33.3%)    0/5 (0%)        5/10 (50%)      0.101
  AHI; mean ± SD                                                  1.4 ± 1.8       0.2 ± 0.3       2.1 ± 2.0       0.036
  OAHI; mean ± SD                                                 1.2 ± 1.7       0.2 ± 0.3       1.7 ± 1.9       0.078
  Mean SpO~2~; mean ± SD[‡](#TFN3){ref-type="table-fn"}           95.7 ± 2.3      96.2 ± 0.4      95.5 ± 2.8      0.458
  SpO~2~ nadir; mean ± SD                                         89.5 ± 3.9      92.7 ± 1.6      87.6 ± 3.7      0.002
  Mean NREM EtpCO~2~; mean ± SD[§](#TFN4){ref-type="table-fn"}    34.3 ± 3.1      34.4 ± 3.4      34.3 ± 3.1      0.954
  Mean REM EtpCO~2~; mean ± SD[§](#TFN4){ref-type="table-fn"}     35.1 ± 2.6      34.6 ± 3.0      35.4 ± 3.5      0.625
  Peak sleep EtpCO~2~; mean ± SD[†](#TFN2){ref-type="table-fn"}   42.1 ± 3.5      42.2 ± 2.9      42.1 ± 4.2      0.983
  Change CO~2~ REM-NREM; n (%)[§](#TFN4){ref-type="table-fn"}     6/12 (50%)      2/5 (40%)       4/7 (57.1%)     1.00

\*n=13;

n=14;

n=15;

n=12.

[Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"} show associations between clinical variables (lung function and chronic PA airway colonization) and PSG findings. FEV~1~ was associated with mean nocturnal SpO~2~ (96.87 ± 1.12% when FEV~1~≥90% and 94.16 ± 2.78% when FEV~1~ \< 90%; *p*=0.027). Chronic PA colonization was associated with mean EtpCO~2~ value during NREM sleep (33 ± 2.77 mmHg in those free from PA and 37 ± 1.41 mmHg in individuals with chronic PA; *p*=0.024). Except for significant associations between Z scores for BMI and Z scores for lung function variables (FEV~1~ and FEF~25-75~) and PA colonization, other clinical data (Shwachman score, number of exacerbations) were not significantly associated with FEV~1~ or PA.

###### 

Comparison between patients with FEV~1~ ≥ 90% and \< 90% of predicted.

  Information                                            FEV~1~≥90% (n=8)   FEV~1~\<90% (n=6)   p
  ------------------------------------------------------ ------------------ ------------------- ---------------------------------------
  Age                                                    11.75±4.74         11.83±5.6           0.976
  BMI Z score                                            0.16±0.57          0.11±0.59           0.897
  Shwachman score^[†](#TFN6){ref-type="table-fn"}^       93.71±5.02         85.5±12.12          0.273
  AHI                                                    1±1.85             1.5±1.87            0.628
  OAHI                                                   0.75±1.48          1.16±1.94           0.656
  Mean SpO~2~                                            96.87±1.12         94.16±2.78          0.027[\*](#TFN5){ref-type="table-fn"}
  SpO~2~ nadir                                           89±3.77            89±4.42             1.00
  Mean NREM EtpCO~2~^[†](#TFN6){ref-type="table-fn"}^    33.86±3.48         35.75±2.21          0.358
  Mean REM EtpCO~2~^[†](#TFN6){ref-type="table-fn"}^     34.85±3.02         36.25±1.25          0.410
  Peak sleep EtpCO~2~^[‡](#TFN7){ref-type="table-fn"}^   41.14±2.41         43.4±5.31           0.340

Significance cutoff (*p*)\<0.05;

n=7 for FEV~1~≥90% and n=4 for FEV~1~ \<90% of predicted;

n=7 for FEV~1~≥90% and n=5 for FEV~1~\<90% of predicted.

FEV~1~=forced expiratory volume in one second SD=standard deviation; BMI=body mass index; AHI=apnea-hypopnea index; OIAH=obstructive AHI index - without central apneas; SpO~2~=oxyhemoglobin saturation; EtpCO~2~=end-tidal carbon dioxide; NREM=non rapid eye movement (REM) stage.

###### 

Comparison between patients with and without chronic Pseudomonas aeruginosa (PA) airway colonization.

  Information                                             With PA (n=9)   Without PA (n=7)   p
  ------------------------------------------------------- --------------- ------------------ ---------------------------------------
  Age                                                     9.44 ± 5.05     12.14 ± 6.22       0.354
  BMI Z score                                             0.40 ± 0.55     -0.22 ± 0.49       0.034[\*](#TFN9){ref-type="table-fn"}
  Shwachman score[†](#TFN10){ref-type="table-fn"}         95.71 ± 3.54    87 ± 10.17         0.093
  FEV~1~ Z score[‡](#TFN11){ref-type="table-fn"}          0.21 ± 1.38     -2.59 ± 2.09       0.011[\*](#TFN9){ref-type="table-fn"}
  FEV~1~/FVC Z score[‡](#TFN11){ref-type="table-fn"}      -0.18 ± 1.1     -1.34 ± 1.34       0.102
  FEF~25-75~ Z score[‡](#TFN11){ref-type="table-fn"}      0 ± 1.34        -2.4 ± 1.74        0.013[\*](#TFN9){ref-type="table-fn"}
  AHI                                                     1.33 ± 1.73     1 ± 1.82           0.715
  OAHI                                                    0.77 ± 1.39     1 ± 1.82           0.786
  Mean SpO~2~[§](#TFN12){ref-type="table-fn"}             96.77 ± 1.09    94.16 ± 2.78       0.071
  SpO~2~ nadir                                            88.88 ± 3.33    90.28 ± 4.78       0.502
  Mean NREM EtpCO~2~[\|\|](#TFN13){ref-type="table-fn"}   33 ± 2.77       37 ± 1.41          0.024[\*](#TFN9){ref-type="table-fn"}
  Mean REM EtpCO~2~[\|\|](#TFN13){ref-type="table-fn"}    34.12 ± 2.64    37 ± 1.15          0.068
  Peak sleep EtpCO~2~[‡](#TFN11){ref-type="table-fn"}     41 ± 2.44       43.66 ± 4.41       0.173

Significance cutoff (*p*)\<0.05;

n=7 without and 6 with chronic airway colonization by *Pseudomonas aeruginosa* (PA);

n=8 without and 6 with PA;

n=6 with PA;

n=8 without and 4 with PA.

SD=standard deviation; BMI=body mass index; FVC=forced vital capacity; FEV~1~=forced expiratory volume in one second; FEF~25-75~=forced expiratory flow from 25% to 75% of FVC; AHI=apnea-hypopnea index; OIAH=obstructive AHI index - without central apneas; SpO~2~=oxyhemoglobin saturation; EtpCO~2~=end-tidal carbon dioxide; NREM=non rapid eye movement (REM) stage.

Correlations were observed between variables associated with CF lung diseases and PSG respiratory variables. There was a correlation between FEV~1~ Z score and peak CO~2~ level ([Figure 1A](#f1){ref-type="fig"}). Moreover, FEV~1~ Z score was correlated with mean sleep SpO~2~ ([Figure 1B](#f2){ref-type="fig"}). Additionally, a correlation was observed between AHI and SpO~2~ nadir ([Figure 1C](#f3){ref-type="fig"}). None of the other correlations were statistically significant.

Figure 1ACorrelation between FEV~1~ (Z score) and the EtpCO~2~ peak.

Figure 1BCorrelation between FEV~1~ (Z score) and mean sleep SpO~2~.

Figure 1CCorrelation between AHI and sleep SpO~2~ nadir.

DISCUSSION
==========

We observed that FEV~1~ was correlated (r=0.602, *p* = 0.023) with mean sleep SpO~2~. Furthermore, FEV~1~ was negatively correlated with peak EtpCO~2~ at night in our pediatric CF population sample. Interestingly, we found that the presence of airway PA colonization exhibited an association with mean EtpCO~2~ during NREM sleep (33 ± 2.77 mmHg *vs.* 37 ± 1.41 mmHg, *p*=0.024). We also found that chronic PA airway colonization exhibited associations with BMI and with lung function parameters, as previously described^[@r26]^. Finally, AHI was negatively correlated with SpO~2~ nadir.

Although recommended in pediatric PSG^[@r27]^, capnography is not always performed for patients with CF. Also, results can be described in different forms: peak and average in sleep (REM and NREM)^[@r10],[@r11]^; during wakefulness^[@r5]^; percent of sleep time with CO~2~ above a cutoff^[@r19]^; and, more recently, by comparing CO~2~ increase in REM sleep in relation to the NREM value (change CO~2~)^[@r15]^. Unlike Waters et al.^[@r15]^, in our study the change CO~2~ ranged from -1 to +3 (CO~2~ in REM sleep increased in relation to NREM in half of the 12 subjects for whom these data were available and remained the same or reduced in the other six subjects) and was not associated with any clinical or functional variables. In our study, FEV~1~ Z score correlated with peak EtpCO~2~ and chronic PA infection was associated with mean CO~2~ in NREM sleep; findings that have not been described previously. When using exhaled CO~2~ measurements, values may be underestimated (compared with transcutaneous CO~2~) in patients with respiratory disease^[@r5],[@r11],[@r16]^. Therefore, we can speculate that if we had used transcutaneous measurement and a larger sample size, we could have found even more consistent findings.

We also observed a correlation between AHI and sleep SpO~2~ nadir, which is expected when evaluating associated respiratory disorders (CF and OSAHS). Most studies seem to agree with our finding^[@r6],[@r9]^, even those employing different definitions for OSAHS. One example is a study Ramos et al.^[@r28]^ conducted with 67 CF patients aged from 2 to 14 years, in which they observed a relationship between an apnea index (number of obstructive and mixed apneas by TST) and lower SpO~2~ values.

It is known that pulmonary function assessment is an essential tool in CF follow-up^[@r29]^, and it has been evaluated in other studies of sleep in CF subjects. Comparing our results to Uyan et al.^[@r14]^, we observed different findings. They did not find a correlation between mean SpO~2~ and FEV~1~ in 24 children with CF (mean age 9.5 years and FEV~1~\> 40%), but did describe an association between SpO~2~ nadir and FEV~1~. In a more recent publication, Spicuzza et al.^[@r9]^ also found no correlation between mean SpO~2~ and FEV~1~ (r^[@r2]^ =0.03, *p* = 0.14). On the other hand, de Castro-Silva et al.^[@r7]^ observed a similar result to ours (correlation between FEV~1~ and mean SpO~2~; *p* \< 0.001). Moreover, Waters et al.^[@r15]^ detected a correlation with baseline SpO~2~, but not with its nadir. They did not report the sleep mean SpO~2~ in their sample of 42 CF patients aged 8 to 12 years^[@r15]^. The reasons for this lack of uniformity may be due to different methodologies used by the studies: 1) regarding the SpO~2~ parameter (mean, nadir, baseline, time and percentage of TST with SpO~2~ below a certain value)^[@r30]^, as in the case of Waters et al.^[@r15]^; 2) regarding the pulmonary function predictive equation used, such as Knudson et al.^[@r31]^ in Uyan and Polgar^[@r32]^ in Waters et al.^[@r15]^ and Spicuzza et al.^[@r9]^; and 3) differences between subjects\' severity profiles in the studies.

One potential implication of our study is the possible inclusion of PSG as part of a routine annual check-up at CF centers. Although there is no consensus on performing PSG in individuals with mild and/or stable disease, there are recent studies suggesting early SDB investigation and PSG may be useful in CF patients^[@r5],[@r6],[@r9]^. In our sample of 16 subjects, only six subjects (37.5%) were classified as normal considering AHI less than or equal to one event per hour of sleep and SpO~2~ nadir greater than or equal to 90% as criteria for normality. Thus, in addition to other results, our impression is that SBD evaluation by PSG has a potential positive impact in CF patients and this benefit may be even greater when considering some subgroups, such as those colonized by PA and those with persistent reductions in pulmonary function parameters, especially FEV~1~.

For instance, it is difficult to describe the immediate clinical relevance of differences observed in our study. Both values were within the normal range, even in subjects colonized by PA. However, we believe these findings may serve as markers for CF respiratory disease progression, rather than revealing a respiratory disturbance.

Small sample size was the most relevant limitation of our study. However, it is known that PSG is not readily available, especially for the pediatric population^[@r33],[@r34]^. Even in countries with greater PSG availability, CF pediatric population studies rarely include more than 40 subjects. Interestingly, Brazilian studies by Ramos et al. have the largest number of individuals (more than 60)^[@r6],[@r28],[@r35]^, but they did not conduct sleep CO~2~ assessment. Nevertheless, we believe our sample size may have been restricted by both the study methodology adopted (a retrospective study) and the PSG access difficulties faced by patients. Ultimately, there are few sleep centers that conduct PSG on children available. Although our study is restricted in quantity, our subjects\' ages and clinical manifestations are comprehensive. This raises two observations: 1) our sample encompasses subjects with different severities; 2) whether it is possible to predict disease progression using PSG.

Finally, we agree with a previous study^[@r5]^ that suggested sleep analysis could serve as an early indicator for CF pulmonary disease progression, although further multicenter studies are necessary to assess PSG findings including nocturnal capnography. The potential positive impact of PSG for pediatric CF patients may be even greater within some subgroups, such as those colonized by PA and those with persistent reductions in pulmonary function parameters, especially FEV~1~.
